U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective for 5- to 11-year-olds. Tuesday's meeting of the FDA panel is the first step toward expanding vaccinations to 28 million youngsters. (Oct. 26)
